Benzinga
13 Nov 2025, 15:15 UTC · 50w ago
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Impact · against what's priced in
MRSN is a clear winner as it is being acquired at a significant premium over its previous valuation. DAWN demonstrates strong commercial momentum with Ojemda revenue guidance raises, though the market is weighing this against the cash outlay for the Mersana acquisition.
- MRSN+1.00
No priced-in read yet
- In context
The company is being acquired for an upfront cash payment of $25.00 per share and up to $30.25 total per share, driving a massive immediate price surge.
Read from the article alone
Search tags
